What does agomelatine do and how effective is it?
What does agomelatine do?
Agomelatine is an antidepressant that acts on brain receptors for melatonin, a hormone that is important for regulating sleep, as well as serotonin receptors. Agomelatine is the only antidepressant that acts on melatonin receptors.
How effective is agomelatine?
Agomelatine is a relatively new medicine, but the data available suggest it may be about as effective as other antidepressants. In trials of other antidepressants, about 50% of people found their depression symptoms were halved.
Although all antidepressants have shown similar efficacy when tested in groups of people in clinical trials, keep in mind that individuals can find one antidepressant works better for them than another. So if the first antidepressant you try doesn’t seem to be working for you after a few weeks, talk to your doctor about switching to another. A psychological therapy, such as cognitive behavioural therapy (CBT), could also be an option.
Find out more about
- Who agomelatine is for and who should be cautious
- Side effects of agomelatine
- Interactions with agomelatine
- Brands of agomelatine
If you are starting agomelatine, see 10 things you should know about antidepressants.
For more information
- Starting, switching and stopping antidepressants
- Managing side effects of antidepressants
- Psychological therapies
The consumer medicine information (CMI) for your brand of agomelatine is available from our website or a pharmacist. The CMI includes:
- how to take this medicine
- what to do if you forget to take it
- if you take too much (overdose)
- things you must and must not do while taking this medicine
- signs of severe reactions and what to do.
- Rossi S, ed. eAMH [online]. Adelaide: Australian Medicines Handbook, 2012. www.amh.net.au. (Accessed 9 February 2012).
- Servier Laboratories (Aust) Pty Ltd. Valdoxan consumer medicine information. July 2010.
- Servier Laboratories (Aust) Pty Ltd. Valdoxan product information. 8 July 2011. www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07273-3 (Accessed 22 March 2012).
- Therapeutic Goods Administration. Australian Public Assessment Report for agomelatine. Canberra: TGA, 2010. www.tga.gov.au/pdf/auspar/auspar-valdoxan.pdf (Accessed 7 March 2012).